Mixed trend on the daily chart: above its 200-day average, below its 50-day · 50-day above the 200-day · SuperTrend down since Sep 25 · inside the Ichimoku cloud · RSI 36 · MACD below its signal
None of the 29 investors followed here reported a position in SYBX in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a SYBX trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Oct 28, 2025 | Dooley Mary BethChief Executive Officer | Sale at price 1.81 per share. | 157 | $284 |
| Apr 24, 2025 | Shea Richard P.Director | Stock Award(Grant) at price 0.00 per share. | 15K | — |
| Apr 24, 2025 | Flynn James PDirector | Stock Award(Grant) at price 0.00 per share. | 15K | — |
| Apr 1, 2025 | Dooley Mary BethOfficer | Sale at price 1.20 per share. | 144 | $173 |
| Feb 2, 2025 | Dooley Mary BethChief Executive Officer | Sale at price 1.33 per share. | 2.1K | $2.80K |
| Oct 28, 2024 | Dooley Mary BethOfficer | Sale at price 1.40 per share. | 79 | $111 |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -43.8 | -1.6 | -1.6 | 3.3 | 7.9 | 3.1 | 71.2 | 1.7 | -8.2 | -5.4 | −5.4% | ||
| 2025 | -0.7 | -1.4 | -9.5 | -8.1 | 0.9 | 10.4 | 21.3 | -5.8 | 15.0 | 1.3 | -13.6 | -23.3 | −20.0% |
| 2024 | -10.4 | -44.6 | -6.3 | 0.0 | -12.8 | -3.8 | 12.7 | -12.4 | 0.7 | -3.4 | -1.7 | -1.1 | −63.6% |
| 2023 | 11.8 | -17.6 | -9.7 | -16.1 | -0.9 | -18.1 | 14.0 | 0.0 | -61.8 | -32.7 | 32.3 | 54.0 | −66.2% |
| 2022 | -13.6 | -5.3 | 21.2 | -29.2 | -35.9 | 5.5 | -15.1 | 2.5 | -5.0 | -11.8 | -28.6 | 27.1 | −68.6% |
| 2021 | 71.8 | 2.2 | -5.5 | -2.5 | 7.2 | 4.0 | -18.8 | -15.2 | 13.8 | -16.1 | -2.7 | -2.8 | +12.0% |
| 2020 | 3.9 | -23.1 | -16.5 | 20.9 | 20.7 | -19.1 | 11.3 | -2.7 | -8.2 | -7.9 | 25.8 | -7.7 | −16.3% |
| 2019 | 15.3 | 7.5 | -12.7 | 13.0 | -13.2 | 22.1 | -38.4 | -50.3 | -17.9 | -6.6 | 0.0 | 20.6 | −63.2% |
| 2018 | 2.8 | 7.6 | -12.6 | 40.5 | -30.0 | 6.6 | -4.7 | 12.9 | 34.3 | -44.3 | 7.6 | -17.6 | −27.7% |
| 2017 | 20.0 | 7.4 | -5.6 | -4.1 | -28.1 | 10.6 | 1.8 | 7.6 | 48.6 | -22.6 | -30.6 | -5.0 | −23.0% |
| 2016 | -27.8 | -3.8 | 0.7 | 5.0 | -5.5 | -1.8 | 2.3 | -42.7 | -21.2 | -36.5 | 23.2 | 16.9 | −71.2% |
| 2015 | -17.4 | -0.9 | 9.1 | −10.7% |
No analyst coverage for this instrument.
Synlogic, Inc. does not have significant operations. It was previously engaged in the discovery and development of synthetic biotics to treat metabolic diseases. Synlogic, Inc. is based in Winchester, Massachusetts.